Zydus Cadila Receives Final Approval From US FDA Stock Up By Nearly 4%

Cadila Healthcare Limited in its BSE filing has said that Zydus Cadila has received final approval from the US FDA to market Budesonide Capsules, 3 mg (Enteric Coated).

It also said that the drug is a corticosteroid used for its anti-inflammatory action, adding that it will be produced at the group’s manufacturing facility at the Pharma SEZ in Ahmedabad. The estimated sales for Budesonide is $285.8 million (IMS MAT March 2017).

The group now has more than 110 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04, it added.

Cadila Healthcare is an Indian pharmaceutical company headquartered at Ahmedabad in Gujarat state of western India. 

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 
Give a Missed Call for Free Trial - 09699997717 
Share on Google Plus Share on Pinterest

About Suhani Varma

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.